Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-7386 + Enzalutamide in mHSPC
NCT06312670Phase 2Completed
- Start
- May 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of masofaniten in prostate cancer (PCa). Primary endpoints: Biochemical Response Rate at Week 4, PSA Progression-Free Survival at Week 4 and 2 more. Started May 2024; status: completed.
02
Drugs
masofaniten
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06312670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06312670.